Evidence map›Paper›PMID 34748611›Full record

ArticlePLoS pathogens2021

Suppression of inflammatory arthritis by the parasitic worm product ES-62 is associated with epigenetic changes in synovial fibroblasts.

Marlene Corbet, Miguel A Pineda, Kun Yang, Anuradha Tarafdar, Sarah McGrath, Rinako Nakagawa, Felicity E Lumb, Colin J Suckling, William Harnett, Margaret M Harnett

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. International journal of molecular sciences · 2024
    Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Marlene CorbetInstitute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom.
Miguel A PinedaInstitute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom.ORCID 0000-0001-5678-7752
Kun YangInstitute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom.
Anuradha TarafdarInstitute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom.
Sarah McGrathInstitute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom.ORCID 0000-0002-5667-9900
Rinako NakagawaImmunity and Cancer, Francis Crick Institute, London, United Kingdom.ORCID 0000-0003-2511-0444
Felicity E LumbStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom.
Colin J SucklingDepartment of Pure and Applied Chemistry, University of Strathclyde, Glasgow, United Kingdom.
William HarnettStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom.ORCID 0000-0001-9545-9401
Margaret M HarnettInstitute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom.ORCID 0000-0001-5740-3028
University of Glasgow · GBUniversity of Strathclyde · GBThe Francis Crick Institute · GB

Funding

Versus Arthritis 21133Versus Arthritis 21221Wellcome Trust 086852
6 · The paper itself

Abstract

ES-62 is the major secreted protein of the parasitic filarial nematode, Acanthocheilonema viteae. The molecule exists as a large tetramer (MW, ~240kD), which possesses immunomodulatory properties by virtue of multiple phosphorylcholine (PC) moieties attached to N-type glycans. By suppressing inflammatory immune responses, ES-62 can prevent disease development in certain mouse models of allergic and autoimmune conditions, including joint pathology in collagen-induced arthritis (CIA), a model of rheumatoid arthritis (RA). Such protection is associated with functional suppression of "pathogenic" hyper-responsive synovial fibroblasts (SFs), which exhibit an aggressive inflammatory and bone-damaging phenotype induced by their epigenetic rewiring in response to the inflammatory microenvironment of the arthritic joint. Critically, exposure to ES-62 in vivo induces a stably-imprinted CIA-SF phenotype that exhibits functional responses more typical of healthy, Naïve-SFs. Consistent with this, ES-62 "rewiring" of SFs away from the hyper-responsive phenotype is associated with suppression of ERK activation, STAT3 activation and miR-155 upregulation, signals widely associated with SF pathogenesis. Surprisingly however, DNA methylome analysis of Naïve-, CIA- and ES-62-CIA-SF cohorts reveals that rather than simply preventing pathogenic rewiring of SFs, ES-62 induces further changes in DNA methylation under the inflammatory conditions pertaining in the inflamed joint, including targeting genes associated with ciliogenesis, to programme a novel "resolving" CIA-SF phenotype. In addition to introducing a previously unsuspected aspect of ES-62's mechanism of action, such unique behaviour signposts the potential for developing DNA methylation signatures predictive of pathogenesis and its resolution and hence, candidate mechanisms by which novel therapeutic interventions could prevent SFs from perpetuating joint inflammation and destruction in RA. Pertinent to these translational aspects of ES-62-behavior, small molecule analogues (SMAs) based on ES-62's active PC-moieties mimic the rewiring of SFs as well as the protection against joint disease in CIA afforded by the parasitic worm product.

Indexed as

Epigenesis, GeneticAcanthocheilonemaAnimalsAnti-Inflammatory AgentsArthritis, ExperimentalCells, CulturedDNA MethylationFibroblastsHelminth ProteinsInflammationMaleMiceMice, Inbred DBASynoviocytesAnti-Inflammatory AgentsES-62 protein, Acanthocheilonema viteaeHelminth Proteins

Identifiers

PMID34748611
PMCPMC8601611
OpenAlexW3212805426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.